SG178095A1 - Antiproliferative compounds, conjugates thereof, methods therefor, and uses thereof - Google Patents

Antiproliferative compounds, conjugates thereof, methods therefor, and uses thereof Download PDF

Info

Publication number
SG178095A1
SG178095A1 SG2012005054A SG2012005054A SG178095A1 SG 178095 A1 SG178095 A1 SG 178095A1 SG 2012005054 A SG2012005054 A SG 2012005054A SG 2012005054 A SG2012005054 A SG 2012005054A SG 178095 A1 SG178095 A1 SG 178095A1
Authority
SG
Singapore
Prior art keywords
compound
alkyl
substituted
unsubstituted
alkenyl
Prior art date
Application number
SG2012005054A
Other languages
English (en)
Inventor
Heng Cheng
Qiang Cong
Sanjeev Gangwar
Qian Zhang
Original Assignee
Medarex Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medarex Inc filed Critical Medarex Inc
Publication of SG178095A1 publication Critical patent/SG178095A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A61K47/6829—Bacterial toxins, e.g. diphteria toxins or Pseudomonas exotoxin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/06—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton
    • C07C229/10—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings
    • C07C229/14—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings to carbon atoms of carbon skeletons containing rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/06—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton
    • C07C229/10—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings
    • C07C229/16—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings to carbon atoms of hydrocarbon radicals substituted by amino or carboxyl groups, e.g. ethylenediamine-tetra-acetic acid, iminodiacetic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/021—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)n-C(=0)-, n being 5 or 6; for n > 6, classification in C07K5/06 - C07K5/10, according to the moiety having normal peptide bonds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
SG2012005054A 2009-08-03 2010-08-02 Antiproliferative compounds, conjugates thereof, methods therefor, and uses thereof SG178095A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US23093209P 2009-08-03 2009-08-03
US23288309P 2009-08-11 2009-08-11
PCT/US2010/044078 WO2011017249A1 (en) 2009-08-03 2010-08-02 Antiproliferative compounds, conjugates thereof, methods therefor, and uses thereof

Publications (1)

Publication Number Publication Date
SG178095A1 true SG178095A1 (en) 2012-03-29

Family

ID=42782224

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201503332XA SG10201503332XA (en) 2009-08-03 2010-08-02 Antiproliferative compounds, conjugates thereof, methods therefor, and uses thereof
SG2012005054A SG178095A1 (en) 2009-08-03 2010-08-02 Antiproliferative compounds, conjugates thereof, methods therefor, and uses thereof

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG10201503332XA SG10201503332XA (en) 2009-08-03 2010-08-02 Antiproliferative compounds, conjugates thereof, methods therefor, and uses thereof

Country Status (28)

Country Link
US (6) US8394922B2 (OSRAM)
EP (1) EP2461830B1 (OSRAM)
JP (1) JP5859964B2 (OSRAM)
KR (1) KR101759359B1 (OSRAM)
CN (2) CN104592351A (OSRAM)
AR (1) AR077701A1 (OSRAM)
AU (1) AU2010279674B2 (OSRAM)
BR (1) BR112012002615A2 (OSRAM)
CA (1) CA2770042C (OSRAM)
CL (1) CL2012000302A1 (OSRAM)
CO (1) CO6501196A2 (OSRAM)
DK (1) DK2461830T3 (OSRAM)
EA (1) EA022288B1 (OSRAM)
ES (1) ES2525351T3 (OSRAM)
HR (1) HRP20140976T1 (OSRAM)
HU (1) HUE026997T2 (OSRAM)
IL (1) IL217717A (OSRAM)
IN (1) IN2012DN00860A (OSRAM)
MX (1) MX2012001665A (OSRAM)
NZ (1) NZ597985A (OSRAM)
PE (1) PE20121087A1 (OSRAM)
PL (1) PL2461830T3 (OSRAM)
PT (1) PT2461830E (OSRAM)
SG (2) SG10201503332XA (OSRAM)
SI (1) SI2461830T1 (OSRAM)
SM (1) SMT201400183B (OSRAM)
TW (1) TWI469794B (OSRAM)
WO (1) WO2011017249A1 (OSRAM)

Families Citing this family (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006012527A1 (en) 2004-07-23 2006-02-02 Endocyte, Inc. Bivalent linkers and conjugates thereof
EP2139523B1 (en) 2007-03-14 2014-10-22 Endocyte, Inc. Conjugates of folate and tubulysin for targeted drug delivery
US9877965B2 (en) 2007-06-25 2018-01-30 Endocyte, Inc. Vitamin receptor drug delivery conjugates for treating inflammation
WO2009002993A1 (en) 2007-06-25 2008-12-31 Endocyte, Inc. Conjugates containing hydrophilic spacer linkers
WO2009026177A1 (en) 2007-08-17 2009-02-26 Purdue Research Foundation Psma binding ligand-linker conjugates and methods for using
IT1394860B1 (it) * 2009-07-22 2012-07-20 Kemotech S R L Composti farmaceutici
US8394922B2 (en) * 2009-08-03 2013-03-12 Medarex, Inc. Antiproliferative compounds, conjugates thereof, methods therefor, and uses thereof
US9951324B2 (en) 2010-02-25 2018-04-24 Purdue Research Foundation PSMA binding ligand-linker conjugates and methods for using
RU2755066C2 (ru) 2010-06-08 2021-09-13 Дженентек, Инк. Полученные с помощью генной инженерии антитела с цистеиновыми заменами и их конъюгаты
WO2012123488A1 (en) * 2011-03-16 2012-09-20 F. Hoffmann-La Roche Ag Ion exchange chromatography with improved selectivity for the separation of polypeptide monomers, aggregates and fragments by modulation of the mobile phase
KR102087854B1 (ko) 2011-06-10 2020-03-12 메르사나 테라퓨틱스, 인코포레이티드 단백질-중합체-약물 접합체
WO2013126797A1 (en) 2012-02-24 2013-08-29 Purdue Research Foundation Cholecystokinin b receptor targeting for imaging and therapy
US20140080175A1 (en) 2012-03-29 2014-03-20 Endocyte, Inc. Processes for preparing tubulysin derivatives and conjugates thereof
CN107982545B (zh) * 2012-05-15 2021-04-09 联宁（苏州）生物制药有限公司 药物偶联物，偶联方法，及其用途
US11873281B2 (en) 2012-07-12 2024-01-16 Hangzhou Dac Biotech Co., Ltd. Conjugates of cell binding molecules with cytotoxic agents
PL2872157T3 (pl) * 2012-07-12 2020-07-13 Hangzhou Dac Biotech Co., Ltd Koniugaty wiążących komórkę cząsteczek ze środkami cytotoksycznymi
EP2708243A1 (en) 2012-09-17 2014-03-19 OntoChem GmbH Receptor ligand linked cytotoxic molecules
EA201590622A1 (ru) 2012-10-16 2015-10-30 Эндосайт, Инк. Конъюгаты для доставки лекарственного средства, содержащие не встречающиеся в природе аминокислоты, и способы применения
KR102499944B1 (ko) 2012-11-15 2023-02-14 엔도사이트, 인코포레이티드 Psma 발현 세포에 의해 야기되는 질병을 치료하기 위한 컨쥬게이트
ES2701076T3 (es) 2012-11-24 2019-02-20 Hangzhou Dac Biotech Co Ltd Enlazadores hidrofílicos y sus usos para la conjugación de fármacos a las moléculas que se unen a las células
EP2928504B1 (en) 2012-12-10 2019-02-20 Mersana Therapeutics, Inc. Protein-polymer-drug conjugates
US9872918B2 (en) 2012-12-12 2018-01-23 Mersana Therapeutics, Inc. Hydroxyl-polymer-drug-protein conjugates
SI2956173T1 (sl) 2013-02-14 2017-06-30 Bristol-Myers Squibb Company Spojine tubulizina, postopki pridobivanja in uporaba
US20140249315A1 (en) * 2013-03-01 2014-09-04 Endocyte, Inc. Processes for preparing tubulysins
CA2906784C (en) 2013-03-15 2023-02-28 The Centre For Drug Research And Development Cytotoxic and anti-mitotic compounds, and methods of using the same
JP6171435B2 (ja) * 2013-03-18 2017-08-02 富士通株式会社 半導体装置及びその製造方法、電源装置、高周波増幅器
WO2014197866A1 (en) 2013-06-06 2014-12-11 Igenica Biotherapeutics, Inc. Modified antibodies and related compounds, compositions, and methods of use
WO2015057585A1 (en) * 2013-10-14 2015-04-23 Regents Of The University Of Minnesota Therapeutic compounds
HRP20240398T1 (hr) 2013-10-18 2024-06-07 Novartis Ag Označeni inhibitori prostata specifičnog membranskog antigena (psma), njihova upotreba kao sredstava za snimanje i farmaceutska sredstva za liječenje raka prostate
EP4541378A3 (en) 2013-11-14 2025-07-30 Endocyte, Inc. Compounds for positron emission tomography
US20170168074A1 (en) 2013-11-25 2017-06-15 Ontochem Gmbh Method for diagnosing G-protein coupled receptor-related diseases
ES2916722T3 (es) 2013-12-27 2022-07-05 Zymeworks Inc Sistemas de enlace que contienen sulfonamida para conjugados de fármacos
US10675355B2 (en) 2013-12-27 2020-06-09 Var2 Pharmaceuticals Aps VAR2CSA-drug conjugates
EP3099681B1 (en) 2014-01-28 2020-12-09 TUBE Pharmaceuticals GmbH Cytotoxic tubulysin compounds and conjugates thereof
AU2014384434B2 (en) 2014-02-28 2016-11-03 Hangzhou Dac Biotech Co., Ltd Charged linkers and their uses for conjugation
WO2015135659A1 (en) 2014-03-14 2015-09-17 Ontochem Gmbh Receptor ligand linked cytotoxic molecules
MX371403B (es) 2014-03-20 2020-01-29 Bristol Myers Squibb Co Moleculas de andamiaje a base de fibronectina estabilizada.
CN106458942A (zh) * 2014-04-11 2017-02-22 麦迪穆有限责任公司 微管溶素衍生物
US9579317B2 (en) * 2014-06-03 2017-02-28 Jiarui Biopharmaceuticals, Ltd. Peptide-drug conjugates
WO2016026458A1 (zh) 2014-08-22 2016-02-25 亚飞（上海）生物医药科技有限公司 一种肿瘤微环境特异激活的小分子靶向偶联体及其用途
CN104262455B (zh) * 2014-08-22 2017-05-03 亚飞（上海）生物医药科技有限公司 肿瘤微环境靶向激活的紫杉醇衍生物及其制备和用途
WO2016040684A1 (en) * 2014-09-11 2016-03-17 Seattle Genetics, Inc Targeted delivery of tertiary amine-containing drug substances
JP2017531620A (ja) 2014-09-12 2017-10-26 ジェネンテック， インコーポレイテッド システイン操作抗体及びコンジュゲート
IL287645B2 (en) 2014-09-17 2024-04-01 Zymeworks Bc Inc Cytotoxic and anti-mitotic compounds, and methods of using the same
US10077287B2 (en) 2014-11-10 2018-09-18 Bristol-Myers Squibb Company Tubulysin analogs and methods of making and use
SI3221363T1 (sl) 2014-11-21 2020-09-30 Bristol-Myers Squibb Company Protitelesa proti CD73 in njihova uporaba
EP3221346B1 (en) 2014-11-21 2020-09-02 Bristol-Myers Squibb Company Antibodies comprising modified heavy constant regions
EP3702367B1 (en) 2014-11-25 2024-05-15 Bristol-Myers Squibb Company Novel pd-l1 binding polypeptides for imaging
US10188759B2 (en) 2015-01-07 2019-01-29 Endocyte, Inc. Conjugates for imaging
CR20170438A (es) 2015-02-25 2018-01-30 Univ Rice William M Desacetoxitubulisina h y análogos de esta
CN107406496A (zh) 2015-03-10 2017-11-28 百时美施贵宝公司 可通过转谷氨酰胺酶缀合的抗体和由其制备的缀合物
PL3303396T3 (pl) 2015-05-29 2023-03-06 Bristol-Myers Squibb Company Przeciwciała przeciwko ox40 i ich zastosowanie
WO2015151081A2 (en) 2015-07-12 2015-10-08 Suzhou M-Conj Biotech Co., Ltd Bridge linkers for conjugation of a cell-binding molecule
US9839687B2 (en) 2015-07-15 2017-12-12 Suzhou M-Conj Biotech Co., Ltd. Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule
ES2809125T3 (es) 2015-09-23 2021-03-03 Bristol Myers Squibb Co Moléculas de armazón a base de fibronectina de unión a glipicano-3
KR101897872B1 (ko) * 2015-09-24 2018-09-12 주식회사 엘지화학 화합물 및 이를 포함하는 유기 발광 소자
US10233212B2 (en) 2015-11-03 2019-03-19 Industrial Technology Research Institute Compounds, linker-drugs and ligand-drug conjugates
JP2019501131A (ja) 2015-12-04 2019-01-17 シアトル ジェネティックス， インコーポレイテッド 四級化チューブリシン化合物の複合体
US11793880B2 (en) 2015-12-04 2023-10-24 Seagen Inc. Conjugates of quaternized tubulysin compounds
EA201891482A1 (ru) 2015-12-21 2018-12-28 Бристол-Маерс Сквибб Компани Модифицированные антитела для сайт-специфической конъюгации
CA3012960A1 (en) 2016-02-01 2017-08-10 Pfizer Inc. Tubulysin analogs and methods for their preparation
SG11201806861SA (en) 2016-03-04 2018-09-27 Bristol Myers Squibb Co Combination therapy with anti-cd73 antibodies
CN105664134B (zh) * 2016-03-13 2019-04-26 浙江药苑生物科技有限公司 一种用于治疗骨癌的药物组合物
EP3454909A1 (en) * 2016-05-10 2019-03-20 Bristol-Myers Squibb Company Antibody-drug conjugates of tubulysin analogs with enhanced stability
US20170326249A1 (en) * 2016-05-10 2017-11-16 Bristol-Myers Squibb Company Antibody-drug conjugate of an anti-glypican-3 antibody and a tubulysin analog, preparation and uses
US10106560B2 (en) 2016-06-16 2018-10-23 Bristol-Myers Squibb Company Process and intermediates for making tubulysin analogs
EP3500574B1 (en) 2016-08-19 2021-11-24 Bristol-Myers Squibb Company Seco-cyclopropapyrroloindole compounds, antibody-drug conjugates thereof, and methods of making and use
US20190218294A1 (en) 2016-09-09 2019-07-18 Bristol-Myers Squibb Company Use of an anti-pd-1 antibody in combination with an anti-mesothelin antibody in cancer treatment
US10517958B2 (en) 2016-10-04 2019-12-31 Zymeworks Inc. Compositions and methods for the treatment of platinum-drug resistant cancer
US10398783B2 (en) 2016-10-20 2019-09-03 Bristol-Myers Squibb Company Antiproliferative compounds and conjugates made therefrom
AU2016429272A1 (en) 2016-11-14 2019-05-02 Hangzhou Dac Biotech Co., Ltd. Conjugation linkers, cell binding molecule-drug conjugates containing the likers, methods of making and uses such conjugates with the linkers
JP6585650B2 (ja) * 2017-03-23 2019-10-02 ハンヂョウ ディーエイシー バイオテック カンパニー リミテッド 細胞毒性剤と細胞結合受容体との共役体
JP7762498B2 (ja) 2017-05-25 2025-10-30 ブリストル－マイヤーズ スクイブ カンパニー 修飾重鎖定常領域を含む抗体
WO2019108685A1 (en) * 2017-11-29 2019-06-06 William March Rice University Tubulysin analogues as anticancer agents and payloads for antibody-drug conjugates and methods of treatment therewith
CN112368024A (zh) 2018-04-17 2021-02-12 恩多塞特公司 治疗癌症的方法
WO2019209811A1 (en) 2018-04-24 2019-10-31 Bristol-Myers Squibb Company Macrocyclic toll-like receptor 7 (tlr7) agonists
JP7458997B2 (ja) 2018-05-29 2024-04-01 ブリストル－マイヤーズ スクイブ カンパニー プロドラッグおよび複合体に使用する修飾自己切断部分ならびにその使用方法および製造方法
US11020490B2 (en) 2018-06-22 2021-06-01 Bristol-Myers Squibb Company Antibody-drug conjugate with a tubulysin analog warhead having a stabilized acetate group in the TUV subunit
JP2022513653A (ja) 2018-11-28 2022-02-09 ブリストル－マイヤーズ スクイブ カンパニー 修飾された重鎖定常領域を含む抗体
EA202191518A1 (ru) 2018-11-30 2021-10-04 Бристол-Маерс Сквибб Компани Антитело, содержащее глутаминсодержащее с-концевое удлинение легкой цепи, его конъюгаты, способы и пути применения
US12478686B2 (en) 2018-12-12 2025-11-25 Bristol-Myers Squibb Company Antibodies modified for transglutaminase conjugation, conjugates thereof, and methods and uses
EA202191769A1 (ru) 2018-12-21 2021-12-08 Регенерон Фармасьютикалз, Инк. Тубулизины и конъюгаты белок-тубулизин
CN114096264B (zh) 2019-05-20 2025-03-14 因多塞特股份有限公司 制备psma缀合物的方法
JP6842127B2 (ja) * 2019-05-22 2021-03-17 ハンヂョウ ディーエイシー バイオテック カンパニー リミテッド 細胞毒性剤と細胞結合受容体との共役体
PH12021553156A1 (en) 2019-06-29 2022-07-25 Hangzhou Dac Biotech Co Ltd Conjugates of tubulysin derivatives and cell binding molecules and methods of making
WO2021055306A1 (en) 2019-09-16 2021-03-25 Bristol-Myers Squibb Company Dual capture method for analysis of antibody-drug conjugates
CN113387829B (zh) * 2020-03-13 2023-04-07 凯特立斯（深圳）科技有限公司 一种沙库必曲的制备方法
WO2021262910A2 (en) * 2020-06-24 2021-12-30 Regeneron Pharmaceuticals, Inc. Tubulysins and protein-tubulysin conjugates
JP7044419B2 (ja) * 2021-02-04 2022-03-30 ハンヂョウ ディーエイシー バイオテック カンパニー リミテッド 細胞毒性剤と細胞結合受容体との共役体
WO2022078524A2 (en) 2021-11-03 2022-04-21 Hangzhou Dac Biotech Co., Ltd. Specific conjugation of an antibody

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1981001145A1 (en) 1979-10-18 1981-04-30 Univ Illinois Hydrolytic enzyme-activatible pro-drugs
US4475196A (en) 1981-03-06 1984-10-02 Zor Clair G Instrument for locating faults in aircraft passenger reading light and attendant call control system
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4631190A (en) 1981-06-26 1986-12-23 Shen Wei C Acidity-sensitive spacer molecule to control the release of pharmaceuticals from molecular carriers
US5144011A (en) 1981-06-26 1992-09-01 Boston University Acidity-sensitive spacer molecule to control the release of pharmaceuticals from molecular carriers
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4486194A (en) 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
US4698420A (en) 1985-02-25 1987-10-06 Xoma Corporation Antibody hybrid molecules and process for their preparation
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US5374548A (en) 1986-05-02 1994-12-20 Genentech, Inc. Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor
MX9203291A (es) 1985-06-26 1992-08-01 Liposome Co Inc Metodo para acoplamiento de liposomas.
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US5108921A (en) 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
US6214345B1 (en) 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates
TW420681B (en) 1995-12-08 2001-02-01 Lederle Japan Ltd Carbapenem-3-carboxylic acid ester derivatives
DE19638870B4 (de) 1996-09-23 2009-05-14 Helmholtz-Zentrum für Infektionsforschung GmbH Tubulysine, Verfahren zu ihrer Gewinnung und sie enthaltende Mittel
US7214487B2 (en) 1998-06-26 2007-05-08 Sunesis Pharmaceuticals, Inc. Methods for identifying compounds that modulate enzymatic activities by employing covalently bonded target-extender complexes with ligand candidates
JP4093757B2 (ja) * 1999-08-24 2008-06-04 メダレックス， インコーポレイテッド ヒトｃｔｌａ−４抗体およびその使用
DE10008089A1 (de) 2000-02-22 2001-10-31 Biotechnolog Forschung Gmbh Syntheseverfahren zur Herstellung von Tubulysinen
PE20020908A1 (es) * 2001-03-21 2002-10-26 Cell Therapeutics Inc Produccion recombinante de polimeros polianionicos y uso de de los mismos
US7087600B2 (en) * 2001-05-31 2006-08-08 Medarex, Inc. Peptidyl prodrugs and linkers and stabilizers useful therefor
US7091186B2 (en) 2001-09-24 2006-08-15 Seattle Genetics, Inc. p-Amidobenzylethers in drug delivery agents
KR100668538B1 (ko) * 2002-01-09 2007-01-16 메다렉스, 인코포레이티드 Ｃｄ３０에 대한 인간 모노클로날 항체
US7816377B2 (en) * 2002-07-09 2010-10-19 R&D-Biopharmaceuticals Gmbh Tubulysin analogues
AU2003253048A1 (en) * 2002-07-09 2004-01-23 Morphochem Aktiengellschaft Fur Kombinatorische Chemie Tubulysin conjugates
DE10241152A1 (de) * 2002-09-05 2004-03-18 GESELLSCHAFT FüR BIOTECHNOLOGISCHE FORSCHUNG MBH (GBF) Tubulysin-Biosynthese-Gene
FR2845630B1 (fr) * 2002-10-09 2005-09-30 Helitest Ags Dispositif de demasticage, notamment pour la refection de joints dans des structures de reservoirs d'aeronefs et container d'intervention
DE10254439A1 (de) * 2002-11-21 2004-06-03 GESELLSCHAFT FüR BIOTECHNOLOGISCHE FORSCHUNG MBH (GBF) Tubulysine, Herstellungsverfahren und Tubulysin-Mittel
TW200510454A (en) 2003-04-15 2005-03-16 Smithkline Beecham Corp Conjugates comprising human IL-18 and substitution mutants thereof
CN1826138B (zh) * 2003-07-22 2012-05-23 舍林股份公司 Rg1抗体及其用途
CA2556752C (en) 2004-02-23 2016-02-02 Genentech, Inc. Heterocyclic self-immolative linkers and conjugates
US7691962B2 (en) * 2004-05-19 2010-04-06 Medarex, Inc. Chemical linkers and conjugates thereof
AU2005244980B2 (en) * 2004-05-19 2011-09-15 E. R. Squibb & Sons, L.L.C. Chemical linkers and conjugates thereof
US7541330B2 (en) 2004-06-15 2009-06-02 Kosan Biosciences Incorporated Conjugates with reduced adverse systemic effects
DE102004030227A1 (de) 2004-06-23 2006-01-26 Dömling, Alexander, Dr. Wirkstoffe mit antiangiogenetischen Eigenschaften
EP3088004B1 (en) 2004-09-23 2018-03-28 Genentech, Inc. Cysteine engineered antibodies and conjugates
NZ556661A (en) * 2005-02-18 2010-10-29 Medarex Inc Human monoclonal antibodies to prostate specific membrance antigen (PSMA)
US7714016B2 (en) * 2005-04-08 2010-05-11 Medarex, Inc. Cytotoxic compounds and conjugates with cleavable substrates
EP3530736A3 (en) 2005-05-09 2019-11-06 ONO Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
WO2007002223A2 (en) * 2005-06-20 2007-01-04 Medarex, Inc. Cd19 antibodies and their uses
EP1948241B1 (en) * 2005-08-19 2014-03-05 Endocyte, Inc. Multi-drug ligand conjugates
JP2009509510A (ja) * 2005-09-26 2009-03-12 メダレックス インコーポレーティッド Ｃｄ７０に対するヒトモノクローナル抗体
AU2006294554B2 (en) * 2005-09-26 2013-03-21 E. R. Squibb & Sons, L.L.C. Antibody-drug conjugates and methods of use
BRPI0619331A2 (pt) * 2005-10-26 2011-09-27 Medarex Inc método para fazer um composto para preparar um análogo de cbi cc-1065, método para preparar um análogo de cbi cc-1065 e composto
CA2627190A1 (en) * 2005-11-10 2007-05-24 Medarex, Inc. Duocarmycin derivatives as novel cytotoxic compounds and conjugates
BRPI0620601A2 (pt) * 2005-12-08 2011-11-16 Medarex Inc anticorpo monoclonal humano isolado ou uma porção ligante ao antìgeno do mesmo, composição, imunoconjugado, molécula de ácido nucléico isolada, vetor de expressão, célula hospedeira, método para preparar um anticorpo anti-o8e e método para tratar ou prevenir uma doença definida pelo crescimento de células tumorais expressando o8e
SI1957539T1 (sl) * 2005-12-08 2013-05-31 Medarex, Inc. Humana monoklonska protitelesa proti protein tirozin kinazi 7 (PTK7) in njihova uporaba
NZ578064A (en) 2006-12-01 2012-01-12 Medarex Inc Human antibodies that bind cd22 and uses thereof
JP2010513306A (ja) 2006-12-14 2010-04-30 メダレックス インコーポレーティッド Ｃｄ７０に結合するヒト抗体およびその使用
UY30776A1 (es) * 2006-12-21 2008-07-03 Medarex Inc Anticuerpos cd44
TWI412367B (zh) 2006-12-28 2013-10-21 Medarex Llc 化學鏈接劑與可裂解基質以及其之綴合物
US20080176958A1 (en) * 2007-01-24 2008-07-24 Insert Therapeutics, Inc. Cyclodextrin-based polymers for therapeutics delivery
US8664407B2 (en) * 2007-02-21 2014-03-04 Medarex, LLC Chemical linkers with single amino acids and conjugates thereof
US20100047841A1 (en) * 2007-02-27 2010-02-25 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Synthesis of desacetoxytubulysin h and analogs thereof
EP2139523B1 (en) * 2007-03-14 2014-10-22 Endocyte, Inc. Conjugates of folate and tubulysin for targeted drug delivery
CA2723671C (en) 2007-05-10 2018-06-19 R & D Biopharmaceuticals Gmbh Tubulysine derivatives
WO2009002993A1 (en) 2007-06-25 2008-12-31 Endocyte, Inc. Conjugates containing hydrophilic spacer linkers
US7387981B1 (en) 2007-06-28 2008-06-17 Lyondell Chemical Technology, L.P. Direct epoxidation catalyst and process
US20110263650A1 (en) 2007-07-20 2011-10-27 Helmholtz-Zentrum Für Infektions-Forschung Gmbh Tubulysin D Analogues
WO2009026177A1 (en) 2007-08-17 2009-02-26 Purdue Research Foundation Psma binding ligand-linker conjugates and methods for using
US8865875B2 (en) 2007-08-22 2014-10-21 Medarex, L.L.C. Site-specific attachment of drugs or other agents to engineered antibodies with C-terminal extensions
DK2195017T3 (en) 2007-10-01 2015-01-19 Bristol Myers Squibb Co Human antibodies that bind mesothelin, and uses thereof
WO2009055562A1 (en) 2007-10-25 2009-04-30 Endocyte, Inc. Tubulysins and processes for preparing
EP2174947A1 (en) * 2008-09-25 2010-04-14 Universität des Saarlandes Bioactive pre-tubulysins and use thereof
US8394922B2 (en) 2009-08-03 2013-03-12 Medarex, Inc. Antiproliferative compounds, conjugates thereof, methods therefor, and uses thereof
WO2011057805A1 (en) * 2009-11-12 2011-05-19 R&D Biopharmaceuticals Gmbh Tubulin inhibitors

Also Published As

Publication number Publication date
US20130197259A1 (en) 2013-08-01
SMT201400183B (it) 2015-01-15
US20160060294A1 (en) 2016-03-03
EP2461830B1 (en) 2014-09-24
US20130204033A1 (en) 2013-08-08
SG10201503332XA (en) 2015-06-29
KR20120047998A (ko) 2012-05-14
IL217717A0 (en) 2012-03-29
AU2010279674B2 (en) 2015-05-07
EA022288B1 (ru) 2015-12-30
US8772543B2 (en) 2014-07-08
CN102725001A (zh) 2012-10-10
US8802632B2 (en) 2014-08-12
KR101759359B1 (ko) 2017-07-18
DK2461830T3 (en) 2015-01-12
SI2461830T1 (sl) 2015-01-30
HRP20140976T1 (hr) 2015-01-02
HUE026997T2 (en) 2016-08-29
CO6501196A2 (es) 2012-08-15
CN104592351A (zh) 2015-05-06
CA2770042C (en) 2017-02-28
AR077701A1 (es) 2011-09-14
US9580467B2 (en) 2017-02-28
US20140323690A1 (en) 2014-10-30
ES2525351T3 (es) 2014-12-22
BR112012002615A2 (pt) 2020-11-03
US20130189256A1 (en) 2013-07-25
IN2012DN00860A (OSRAM) 2015-07-10
US8772542B2 (en) 2014-07-08
US20110027274A1 (en) 2011-02-03
CL2012000302A1 (es) 2012-07-20
MX2012001665A (es) 2012-03-26
PE20121087A1 (es) 2012-08-17
IL217717A (en) 2017-06-29
CA2770042A1 (en) 2011-02-10
JP2013501055A (ja) 2013-01-10
US9226974B2 (en) 2016-01-05
HK1164751A1 (en) 2012-09-28
TWI469794B (zh) 2015-01-21
PL2461830T3 (pl) 2015-03-31
EP2461830A1 (en) 2012-06-13
WO2011017249A1 (en) 2011-02-10
JP5859964B2 (ja) 2016-02-16
AU2010279674A1 (en) 2012-02-23
CN102725001B (zh) 2015-01-14
PT2461830E (pt) 2014-12-11
TW201106976A (en) 2011-03-01
US8394922B2 (en) 2013-03-12
EA201270242A1 (ru) 2012-07-30
NZ597985A (en) 2013-08-30

Similar Documents

Publication Publication Date Title
US9580467B2 (en) Antiproliferative compounds, conjugates thereof, methods therefor, and uses thereof
US9688721B2 (en) Tubulysin compounds, methods of making and use
HK1164751B (en) Antiproliferative compounds, conjugates thereof, methods therefor, and uses thereof
HK1212209B (en) Tubulysin compounds, methods of making and use